TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal; Arun Azad; Neal D Shore; Joan Carles; Andre P Fay; Curtis Dunshee; Lawrence Ivan Karsh; Maria Luisa Paccagnella; Nicola Di Santo; Mohamed Elmeliegy; Xun Lin; Alexander Niyazov; Akos Czibere; Karim Fizazi

Conference Proceedings

TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal, Arun Azad, Neal D Shore, Joan Carles, Andre P Fay, Curtis Dunshee, Lawrence Ivan Karsh, Maria Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Alexander Niyazov, Akos Czibere, Karim Fizazi

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021

DOI: 10.1200/jco.2021.39.15_suppl.tps5089

Abstract

TPS5089 Background: TALA blocks poly(ADP-ribose) polymerase (PARP) activity and traps PARP on single-strand DNA breaks, preventing DNA damage repair (DDR) and causing death of cells with DDR alterations (eg, BRCA1/2).a TALA is approved in multiple countries as monotherapy for germline BRCA1/2-mutated human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Olaparib and rucaparib are PARP inhibitors approved for use in mCRPC. ENZA is an androgen receptor (AR) inhibitor and an established therapy for mCRPC. As PARP activity has been shown to support AR function, inhibition of PARP is expected to increase sensitivity to AR-directed therapies. In addition, AR blockade do..

View full abstract